This federal contract award was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Stemcell Technologies Inc., a subsidiary of the Canadian company Stemcell Technologies. The $17,325.95 firm-fixed-price purchase order does not have a set-aside designation.
Stemcell Technologies Inc. is a key supplier of specialized biological materials, laboratory supplies, scientific equipment, and proprietary products to support biomedical research initiatives across various U.S. government agencies, particularly within the Department of Health and Human Services. The company holds a significant $10,000,000 Blanket Purchase Agreement (BPA) with the NIH Office of Logistics and Acquisition Operations, which allows for streamlined procurement of commonly used research materials across NIH institutes and centers.
Through this contract award and the broader BPA, Stemcell Technologies Inc. provides a wide range of products to support critical biomedical research efforts, including cell isolation and enrichment kits, cell culture media, specialized laboratory equipment, and various reagents and consumables. These essential tools and materials are utilized in stem cell research, immunology, cancer studies, and infectious disease investigations conducted by federal research institutions.